Pila Pharma Q2’22: An Aspiring TRPV1 Platform Company
Research Note
2022-08-26
10:18
Redeye comments on Pila Pharma’s Q2 report. Highlights from the quarter include receiving ODD for XEN-D0501 and the commencement of the toxicological studies with XEN-DIA. We fine-tune our valuation model.
FE
Filip Einarsson
Disclosures and disclaimers